




August 28, 2023 — Telescope's first Canadian patent describes a scalable manufacturing process to produce pharmaceutically-relevant indole compounds.
August 3, 2023 — Telescope has granted 800,000 incentive stock options to certain directors of the Company in accordance with the Company’s incentive stock option plan.
July 11, 2023 — Canada's Mining Innovation Commercialization Accelerator ("MICA") Network will fund Telescope's efforts to develop lithium carbonate production methods that are carbon-negative.
June 29, 2023 — The Company generated revenues of $1.01M and a net income of $67,847 in Q3, 2023, representing an increase of 500% in net income over the previous quarter.
We will be out in full force at Canada's largest chemistry conference this year. CSC 2023 is coming to our hometown of Vancouver, and here's where catch us!

Telescope Innovations is Granted a Canadian Patent on Chemical Synthesis Route
August 28, 2023 — Telescope’s first Canadian patent describes a scalable manufacturing process to produce pharmaceutically-relevant indole compounds.

Telescope Announces Stock Option Grants
August 3, 2023 — Telescope has granted 800,000 incentive stock options to certain directors of the Company in accordance with the Company’s incentive stock option plan.

Telescope Innovations Receives Accelerator Funding to Develop Carbon-Negative Production of Battery Materials
July 11, 2023 — Canada’s Mining Innovation Commercialization Accelerator (“MICA”) Network will fund Telescope’s efforts to develop lithium carbonate production methods that are carbon-negative.

Telescope Innovations Delivers Continued Profitability in Fiscal Quarter 3, 2023
June 29, 2023 — The Company generated revenues of $1.01M and a net income of $67,847 in Q3, 2023, representing an increase of 500% in net income over the previous quarter.

Telescope at CSC 2023
We will be out in full force at Canada’s largest chemistry conference this year. CSC 2023 is coming to our hometown of Vancouver, and here’s where catch us!

Telescope Reports Profitable Quarter: Fiscal Q2, 2023
April 25, 2023 — Just over one year after securing facilities, assembling a team, and outfitting a research laboratory, the Company delivered its first profitable quarter.

Telescope Reports First Fiscal Quarter 2023 Results
February 8, 2023 — Telescope is revenue-positive for a second consecutive quarter. Catch us at a series of upcoming investor events and technical conferences.

Telescope Presents 2022 Fiscal Year Highlights and Investor Update
January 23, 2023 — Telescope reports revenue in first full year of operation, a new project with Aqualung Carbon Capture, and upcoming events.

Telescope Announces Closing of $1.46 Million Non-brokered Private Placement
November 10, 2022 — Telescope intends to use the net proceeds from the Offering for working capital and general corporate purposes.

Takeaways From our Press Release on NRCan Project
October 31, 2022 — View PR highlights and watch the video on how this project supports Telescope’s goals

Telescope Announces Engagement with Natural Resources Canada to Develop Lithium Refinement Technology
October 24, 2022 — Telescope will collaborate with NRCan to build an autonomous, self-driving experimental platform for lithium refinement.

Second Nobel Prize Won by Telescope Innovations Advisor
October 6, 2022 — K. Barry Sharpless, a member of Telescope’s Scientific Advisory Board, was awarded the 2022 Nobel Prize in Chemistry.

Telescope welcomes Dr. Jeffrey Sherman as Chief Operating Officer
September 6, 2022 — Dr. Sherman brings over thirty years of experience in the scientific instrument industry, including work with Micromeritics Instrument Corporation, ThermoFisher Scientific, and Mettler-Toledo.

Telescope upgrades US listing to OTCQB
September 1, 2022 — We anticipate that our OTCQB listing will provide greater liquidity and a more seamless trading experience for our U.S. shareholders.

Contextualizing our completed research project funded by Pfizer
August 13, 2022 —We are deploying our unique technology platforms to resolve critical bottlenecks in the chemical and pharmaceutical industry.

Telescope completes feasibility research project funded by Pfizer
August 10, 2022 — We created a proof-of-concept robotic workflow leveraging our proprietary in-situ analytical technology and automation tools.

Telescope inks research agreement with Standard Lithium
July 13, 2022 — Telescope will initially work on developing CO2 utilization and sequestration technology.

Telescope launches first automation product
June 27, 2022 — The Direct Inject Liquid Chromatography (“DILC”) platform is an innovative instrument for real-time, immediate analysis of chemical reactions.

Telescope Announces Results of its Annual General Meeting
April 29, 2022 — Shareholders elected Prof. Jason Hein, Robert Mintak, James Andrew Robinson, Ali Pejman, and Henry Dubina as directors of the Company.

Telescope expects proposal for a new board member at upcoming AGM
April 26, 2022 — Henry Dubina, the ex-president and strategic business unit head of Mettler-Toledo Autochem, is expected to be nominated as an independent director of Telescope.

Telescope Launches Strategic Division for Industrial Chemical Manufacturing and Announces First Client
April 25, 2022 — “Telescope Industries” is a division of the Company dedicated to resolving process and manufacturing inefficiencies in the chemical industry. For its first project, Telescope Industries has been engaged by Hatch Ltd., a global engineering, project management, and professional services firm.

Telescope Announces Testing of Proprietary Compounds for Psychedelic Therapeutic Potential
March 14, 2022 — Positive results from these studies could warrant preclinical development of Telescope’s proprietary compounds as next-generation psychedelic therapeutics.

Telescope Provides a Corporate Update
March 1, 2022 — Over the past year, we have established a growing intellectual property portfolio on pharmaceutical manufacturing,
increased in-house research capacity and proprietary research platforms, and brought in award winning scientific leadership.

Telescope Files Patent Cooperation Treaty Application on Scalable Psilocybin and Tryptamine Synthesis
Jan 17, 2022 — This patent represents a key milestone in addressing the impending manufacturing bottleneck for pharmaceutical-grade psilocybin and psychedelic tryptamines.

Telescope Announces Acquisition of Rights to Synthetic Psilocybin Research
Nov 29, 2021 — We are excited to have come to this agreement with UBC allowing us freedom to own and continue developing our intellectual property.